Brief: Sumitomo Pharma America Enters Into A Cooperative Research And Development Agreement With The National Cancer Institute To Advance Clinical Understanding Of Enzomenib
14/04/2025 14:18
April 14 (Reuters) - Sumitomo Pharma Co Ltd 4506.T: SUMITOMO PHARMA AMERICA ENTERS INTO A COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH THE NATIONAL CANCER INSTITUTE TO ADVANCE CLINICAL UNDERSTANDING OF ENZOMENIB Source text: ID:nPn1dbnkFa Further company coverage: 4506.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)